logo

For the Inventor, By the Inventor

Fremont, CA, United States of America

Quark Pharmaceuticals, Inc.


USPTO Granted Patents = 67



Forward Citations = 378

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Elena Feinstein (56 out of 74 patents)

silverMedal Igor Mett (21 out of 44 patents)

bronzeMedal Hagar Kalinski (17 out of 25 patents)

4.  Sharon Avkin-Nachum (16 out of 21 patents)

5.  Svetlana Adamsky (6 out of 6 patents)

6.  Igor Spivak (6 out of 6 patents)

7.  Rami Skaliter (6 out of 12 patents)

8.  Shai Erlich (5 out of 8 patents)

9.  Evgenia Alpert (5 out of 6 patents)

10.  Amir Bar-Ilan (5 out of 5 patents)

11.  Shai Ehrlich (5 out of 5 patents)

12.  Klaus Giese (4 out of 27 patents)

13.  Jörg Kaufmann (4 out of 32 patents)

14.  James D Thompson (3 out of 3 patents)

15.  Daniel Zurr (3 out of 3 patents)


Core Competencies:
Double-Stranded Oligonucleotides
siRNA Compounds
Oligonucleotide Modulators
Neuroprotection
Cancer Treatment
Ischemia Reperfusion Injury
Toll-Like Receptor Pathway
Hearing Disorders
RTP801 Inhibitors
Oligoribonucleotides
Chronic Kidney Disease
Eye Disorders

67 patents:

1. 10781449 - Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof (2020-09-22),
2. 10570394 - Double-stranded RNA compounds to CASP2 and uses thereof (2020-02-25),
3. 10494631 - siRNA compounds comprising terminal substitutions (2019-12-03),
4. 10421962 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2019-09-24),
5. 10144928 - Double stranded oligonucleotide compounds comprising positional modifications (2018-12-04),
6. 9993567 - Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases (2018-06-12),
7. 9932578 - Double-stranded oligonucleotide molecules to P53 and methods of use thereof (2018-04-03),
8. 9868953 - Methods and compositions for preventing ischemia reperfusion injury in organs (2018-01-16),
9. 9822362 - Compositions and methods for treating lung disease and injury (2017-11-21),
10. 9796979 - Oligonucleotide modulators of the toll-like receptor pathway (2017-10-24),
11. 9738896 - Methods and compositions for neuroprotection (2017-08-22),
12. 9701961 - Methods for treating eye disorders (2017-07-11),
13. 9701960 - siRNA compounds comprising terminal substitutions (2017-07-11),
14. 9611474 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2017-04-04),
15. 9611473 - Double-stranded nucleic acid compounds (2017-04-04),
Quark Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel RNA interference-based therapeutics. With a diverse pipeline of investigational drugs, Quark Pharma aims to address unmet medical needs in various therapeutic areas, including oncology, ophthalmology, and infectious diseases. Through its innovative platform technologies, the company seeks to deliver targeted and effective treatments that have the potential to improve patient outcomes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

67 Patents

#33 in Fremont, CA

#1,238 in California

#5,228 in US

#10,618 in the World

...
Fremont, CA, United States of America

Quark Pharmaceuticals, Inc.

Forward Citations = 378

40 inventors:

goldMedal Elena Feinstein (56 out of 74 patents)

silverMedal Igor Mett (21 out of 44 patents)

bronzeMedal Hagar Kalinski (17 out of 25 patents)

4.  Sharon Avkin-Nachum (16 out of 21 patents)

5.  Svetlana Adamsky (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com
Loading…